CoChat

Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Abstract

Although the epidermal growth factor receptor (EGFR) is overexpressed and/or amplified in more than 50 % of all glioblastomas (GBM), therapeutic targeting of the EGFR has not yet been successful. Since histone deacetylases (HDAC) have been described as controlling EGFR expression, we combined the EGFR tyrosine kinase inhibitor erlotinib with different HDAC inhibitors (HDACi) and investigated the benefit of combinatorial therapy for glioblastoma cells. Using representative models of EGFR-amplified, erlotinib-sensitive and -resistant GBM with or without EGFRvIII expression, we determined proliferation, migration, and EGFR-dependent signaling in response to erlotinib and HDACi alone or in combination. HDACi significantly inhibited proliferation of erlotinib-resistant GBM cells, partially restored their sensitivity to erlotinib, and also significantly reduced proliferation of all treatment-naïve cell lines tested. In combination with erlotinib, the development of resistance was prevented. The multitargeted EGFR/HDAC-inhibitor CUDC-101 exhibited similar effects. However, inhibition of cell migration was only achieved by targeting EGFR, and HDACi exhibited no additive effect. Mechanistically, we identified an HDACi-dependent decrease of EGFR/EGFRvIII protein expression underlying the anti-proliferative effects of HDACi. In conclusion, HDACi in combination with erlotinib might serve as a treatment option for newly diagnosed, treatment-naïve tumors irrespective of their EGFR status, as well as for treatment-refractory, EGFR-overexpressing GBM.

Overview

Integrity signals

Registry

Crossref · 10.1007/s11523-015-0372-y

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 47 references

Cited by

See all 41

Metadata

Authors
Liffers, K., Kolbe, K., Westphal, M., Lamszus, K., & Schulte, A.
Affiliations
University Medical Center Hamburg-Eppendorf (DE)
Corresponding author
Schulte, Alexander
Venue
Targeted Oncology
Published
2015-06-03
Volume
11
Issue
1
Pages
29-40
ISSN
  • 1776-2596 (ISSN-L)
  • 1776-260X
OpenAlex
W562420810
Cited by
41
References
47
Citations by year
2026: 1 · 2025: 4 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 5 · 2020: 5 · 2019: 4 · 2018: 3 · 2017: 4 · 2016: 6 · 2015: 3
FWCI
2.99
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Targeted Oncology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords
histone deacetylase inhibitors, erlotinib, EGFR, EGFRvIII, glioblastoma, drug resistance, tyrosine kinase inhibitors, combination therapy, CUDC-101, cell proliferation, cell migration
MeSH terms
Erlotinib Hydrochloride, Cell Movement, Glioblastoma, Humans, RNA, Messenger, Tumor Cells, Cultured, Blotting, Western, Apoptosis, Drug Resistance, Neoplasm, Reverse Transcriptase Polymerase Chain Reaction, Protein Kinase Inhibitors, Cell Proliferation, Histone Deacetylase Inhibitors, Real-Time Polymerase Chain Reaction, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition. https://app.cochat.ai/papers/10.1007/s11523-015-0372-y
The paper
Liffers, K., Kolbe, K., Westphal, M., Lamszus, K., & Schulte, A. (2016). Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition. Targeted Oncology. https://doi.org/10.1007/s11523-015-0372-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.